Provided are a gene carrier using cell-derived nanovesicles and a method for preparing the same. The gene carrier prepared by inserting a gene into the nanovesicles artificially outbudded from a plasma membrane has excellent delivery efficiency to a target organ and cells, induces long-term regulation of gene expression, and facilitates mass production due to a simple preparation process, and thus can be used as a core technique for the gene or cell therapeutic agent field.

Disclosed are an inflammation-targeted neutrophil granulocyte drug delivery system and use thereof, wherein the drug delivery system includes neutrophil granulocytes and a therapeutic substance or a detectable substance loaded into the neutrophil granulocytes or onto the surface of the neutrophil granulocytes in a direct or indirect way. By using the neutrophil granulocytes as a carrier of a drug, the drug is actively targeted to an inflammatory site, thereby increasing the drug concentration at the inflammatory site. Under the stimulation of cytokines, the neutrophil granulocytes arriving at the inflammatory site are abnormally activated, disintegrate rapidly, and die in the way of “Neutrophil extracellular traps (NETs)”. This helps to rapidly release the loaded drug to the targeted site, so as to improve the therapeutic effect and reduce the toxic and side effects.

The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.

Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.

The present invention relates to a method for producing extracellular vesicles (EV) in large quantities by using a peptide derived from Noxa protein that plays a key role in apoptosis and derivatives thereof, and the use of the peptide for promoting extracellular vesicle production and the method for producing extracellular vesicles by using the same of the present invention can efficiently and uniformly mass-produce extracellular vesicles, and can produce extracellular vesicles which load drugs passing poorly through cellular membranes as well as recombinant proteins or plasmid DNA.

[Problem] To provide: a lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration, contains a lipid that is bound to a peptide composed of multiple arginine residues as a constituent lipid, and includes a bacterial cell component having dispersibility in a non-polar solvent; and a method for producing a lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration and includes a substance of interest having dispersibility in a non-polar solvent. [Solution] A lipid membrane structure which has such a particle diameter that the lipid membrane structure can be sterilized by filtration, contains a lipid that is bound to a peptide composed of multiple arginine residues as a constituent lipid, and includes a bacterial cell component having dispersibility in a non-polar solvent.

A use of prevention or treatment of lung cancer including an antibody specifically recognizing CD66c in lung cancer or its antigen-binding fragment and a chemotherapeutic agent is provided.

The invention concerns the use of bacterial ghosts as carrier and targeting vehicles for active substances.

Pharmaceutical composition and delivery system for prevention and treatment of candidiasis featuring a composition of thymol oil, eugenol oil, and/or carvacrol oil encapsulated in microcapsules, with the microcapsules embedded in a medicated microbial cellulosic matrix. The cellulosic matrix may in turn be embedded in or form a conveyance material, such as a panty liner, a mucoadhesive patch, or chewing gum.

The present invention pertains to extracellular vesicle (EV) therapeutics, wherein the EVs comprise nucleic acid (NA)-based therapeutics such as mRNAs, circular RNAs, miRNAs, shRNAs, and/or DNA molecules. The NA therapeutics are loaded into EVs using inventive protein and NA engineering strategies which stabilize the cargo NAs and enhance loading into EVs, thereby enhancing therapeutic activity of the cargo NA molecules half-life.